“…During the presence of advanced glycation end products (AGEs) and high glucose levels with autophagy, atherosclerosis [378], cardiac disease [379], and endoplasmic reticulum stress [380] can be present. Therapy designed to improve glucose regulation with the activation of autophagy may reduce heart and liver mass [177], reduce cerebral interneuron progenitor cell survival [381], foster death of neurons [382][383][384], enhance memory loss [132,362,[385][386][387][388], and potentially injure mitochondria [46,50,178,197,220,235,343,366,[389][390][391][392]. Cellular protection with growth factors, such as EPO, requires a reduction in autophagy activation in combination with the mechanistic target of rapamycin (mTOR), protein kinase B (Akt), the proline rich Akt substrate 40 kDa (PRAS40), and mammalian forkhead transcription factors [290,306,310,340,341,[343][344][345]362,[393][394][395][396][397][398][399].…”